Carmilia Jiménez Ramírez - President and Chief Advisor

My current mission as President and Chief Consultant is to deliver tailored strategies that bolster regulatory compliance and operational excellence within biopharmaceutical organizations. Mastering bioassay, GLP, and biochemistry has equipped me to offer services from method development to technology transfer, ensuring products meet the most rigorous of standards.

My leadership is characterized by establishing and implementing global business practices and fostering cross-departmental collaboration. Our services aim to provide successful lifecycle management of clinical and commercial biopharmaceutical products, demonstrating a steadfast commitment to innovation and quality in addressing critical medical needs. 

Carmilia Jiménez Ramírez is recognized for her extensive expertise in quality control and analytical technologies. She currently serves as the President and Chief Consultant of Miliar BioPharma Solutions, a consulting firm she established after a successful career in various leadership roles. 

Carmilia’s professional journey includes significant positions at prominent companies such as BioMarin Pharmaceutical Inc., Ajinomoto Bio-Pharma Services, Gilead Sciences, Merck & Co., Inc., and Amgen Inc. In these roles, she focused on the management of biologics programs across multiple therapeutic areas, including oncology, hematology, rheumatology, and renal diseases. 

Carmilia earned her Bachelor of Science degree in Biology from the University of Puerto Rico, Mayagüez. She then pursued a Ph.D. in Microbiology and Immunology at Temple University’s Lewis Katz School of Medicine. Her postdoctoral research was conducted at St. Jude Children’s Research Hospital in Memphis, Tennessee. 

Beyond her professional and academic achievements, Carmilia is actively involved with CASSS – Sharing Science Solutions, an organization dedicated to advancing scientific knowledge in the field of biopharmaceuticals. She has been a member of the CASSS Board of Directors since 2021 and has contributed to multiple committees, including WCBP, the CMC Strategy Forum for Latin America and North America and the Symposium on mRNA Therapy Products.

Carmilia’s dedication to technical innovation and quality control in biopharmaceuticals has significantly contributed to ensuring patient access to superior medical treatments. Her leadership and expertise continue to influence the industry positively.